Based on serious side effects in patients treated with a TCR targeting MAGE-A3 and -A9, that was cross-reactive with MAGE-A12 expressed in brain (47), overlap or minor differences in peptide sequences between tumor and ubiquitously expressed antigens is probably not acceptable. Here, MAGEA3 is linked to neoplasm.